Familial Juvenile Hyperuricemic Nephropathy (FJHN)

Familial juvenile hyperuricemic nephropathy is a rare, inherited kidney disease. It runs in families in an autosomal-dominant way (if a parent has it, each child has a 50% chance). The disease mainly affects the kidney tubules (the kidney’s tiny pipes) and the tissue around them. Over years, those tubules scar and shrink, so kidney function slowly falls. From a young age, people develop high uric acid in the blood and often gout. Urinalysis is usually “bland” (little or no blood or protein in the urine), and kidneys may look normal early on but gradually become small and scarred. Today, doctors group FJHN within a broader family of disorders called autosomal dominant tubulointerstitial kidney disease (ADTKD). The most common form is caused by changes in the UMOD gene (the gene for uromodulin, also called Tamm-Horsfall protein). NCBI+2NCBI+2

Why uric acid rises: the diseased tubules do not handle salt and water normally. That mild salt loss signals the body to reabsorb more urate upstream, so blood uric acid climbs and gout can appear in the teen years or early adulthood. Over decades, chronic kidney disease (CKD) progresses and many people eventually need dialysis or a kidney transplant, often in mid-adulthood. PubMed+1

FJHN is an inherited kidney condition where the tiny tubes in the kidneys slowly scar and work less well. People often have high uric acid in the blood (hyperuricemia), early gout, and chronic kidney disease (CKD) that gets worse over years. Many cases are caused by changes (variants) in the UMOD gene; related conditions can also come from REN and other genes. Doctors now group FJHN under ADTKD, especially ADTKD-UMOD, which has a similar pattern of kidney damage and high uric acid. NCBI+1

Why it happens. In ADTKD-UMOD, the faulty uromodulin protein builds up inside kidney cells, stressing and damaging them. The kidneys then leak less uric acid into urine, so uric acid stays high in the blood. Over time, scarring in the kidney’s tubules causes the filtering rate to drop and can lead to kidney failure in adulthood. ADTKD-REN can have anemia and other features in childhood, but the shared story is a slow, tubule-first kidney disease. NCBI+1

Other names you may see

Doctors and labs may use older or newer names for the same clinical picture. These include:

• Uromodulin-associated kidney disease (UAKD)

• ADTKD-UMOD (autosomal dominant tubulointerstitial kidney disease due to UMOD)

• UMOD-kidney disease

• Medullary cystic kidney disease type 2 (MCKD2) (historical, allelic condition)

• Familial interstitial nephritis with gout (descriptive)
  These labels reflect changing genetics and classification; current practice favors ADTKD-UMOD for the classic FJHN picture. NCBI+2Orpha+2

Types

FJHN fits inside ADTKD. Subtypes are defined by the gene involved:

1. ADTKD-UMOD (classic FJHN): UMOD gene variants; hyperuricemia/gout common; bland urine; slowly progressive CKD. NCBI

2. ADTKD-REN: REN gene variants; often childhood onset with anemia, mild low blood pressure, high potassium, metabolic acidosis; hyperuricemia may occur. PubMed+1

3. ADTKD-MUC1: MUC1 frameshift variants; CKD with bland urine; gout less prominent; requires special assays to detect the typical cytosine-insertion mutation. PubMed

4. ADTKD-HNF1B: HNF1B variants; kidney malformations/cysts, diabetes or other systemic features may be present. PubMed

5. ADTKD-SEC61A1 (rare): resembles other ADTKD forms; confirms genetic diversity of this group. PubMed

In everyday practice, when someone presents with the FJHN pattern (early hyperuricemia/gout, bland urine, family history, slowly progressive CKD), ADTKD-UMOD is the most likely type. NCBI

---

Causes and contributing mechanisms

1. Pathogenic variants in the UMOD gene — the main cause of classic FJHN/ADTKD-UMOD. These changes make uromodulin protein misfold and build up inside tubular cells. NCBI+1

2. Endoplasmic reticulum (ER) stress — misfolded uromodulin clogs the cell’s protein-folding factory (ER), stressing and injuring tubule cells. PubMed

3. Tubular cell death and interstitial scarring — ongoing stress causes tubule loss and scarring (fibrosis), which slowly lowers kidney function. PubMed

4. Impaired salt handling in the thick ascending limb — uromodulin normally supports transporters like NKCC2 and ROMK; dysfunction leads to subtle salt wasting and downstream effects. PubMed

5. Low fractional excretion of urate — kidneys reabsorb too much urate, so blood uric acid rises. This is a hallmark biomarker in many patients. NCBI

6. Gout from hyperuricemia — urate crystals deposit in joints and soft tissue (tophi), causing attacks of painful arthritis. NCBI

7. Progressive CKD — loss of working tubules slowly reduces glomerular filtration rate, often leading to kidney failure in adulthood. MedlinePlus

8. ADTKD-REN variants — less common FJHN-like presentation caused by renin gene changes; can show anemia, hyperkalemia, and acidosis in childhood. PubMed+1

9. ADTKD-MUC1 variants — MUC1 frameshift protein accumulates; causes CKD with bland urine, sometimes mistaken for “cryptic” FJHN. PubMed

10. ADTKD-HNF1B variants — transcription factor defects that disturb kidney development and function; overlap with cystic changes and diabetes. PubMed

11. ADTKD-SEC61A1 variants — rare trafficking/ER-translocation defects that injure tubules. PubMed

12. Reduced urinary uromodulin — despite intracellular buildup, less uromodulin reaches urine; low urinary uromodulin can support the diagnosis. Annual Reviews

13. Family inheritance pattern (autosomal dominant) — one gene copy is enough to cause disease; vertical transmission across generations is typical. NCBI

14. Modifier genes/common UMOD variants — common variants modulate kidney function and CKD risk in the population and may influence severity. PubMed+1

15. Age — disease often appears in teens/young adults (hyperuricemia/gout) and progresses with age. NCBI

16. Purine-rich diets or dehydration (triggers, not root causes) — can precipitate gout flares or raise uric acid further in those already predisposed. (General gout physiology; used as triggers on top of genetic disease.) NCBI

17. NSAID overuse in gout — pain medicines like NSAIDs can worsen kidney function if used heavily or in advanced CKD (not the cause of FJHN, but can hasten decline). (Inference from CKD care standards referenced in ADTKD overviews.) MedlinePlus

18. Hypertension as CKD progresses — high blood pressure develops later and further damages kidneys (a complication that accelerates loss of function). PubMed

19. Intercurrent illnesses — episodes that lower kidney perfusion (e.g., dehydration, severe infection) can cause stepwise drops in function on top of the chronic decline. (General CKD principle applied to ADTKD.) PubMed

20. Diagnostic delay — late recognition (because urine looks “too normal”) means years without risk-reduction counseling; earlier identification helps avoid avoidable hits to kidney function. PubMed

---

Symptoms

1. High uric acid without symptoms — often found on routine blood tests in childhood/teen years. NCBI

2. Gout attacks — sudden joint pain, redness, swelling (often the big toe, ankles, knees) starting in teens or young adults. NCBI

3. Tophi — firm urate lumps on ears, fingers, elbows in long-standing hyperuricemia. (Common gout feature noted in ADTKD-UMOD cohorts.) NCBI

4. Thirst and frequent urination — reduced ability to concentrate urine. PubMed

5. Mild salt craving or dizziness — subtle salt wasting can cause lightheadedness, especially in hot weather/illness. PubMed

6. Fatigue — from CKD and, in ADTKD-REN, from early anemia. PubMed

7. Nausea/poor appetite — with advanced CKD. MedlinePlus

8. Itchy skin — in later CKD stages. MedlinePlus

9. Leg swelling — typically mild and later; heavy proteinuria is unusual. PubMed

10. High blood pressure — often develops as kidney function falls. PubMed

11. No or very mild urinary symptoms — urinalysis is usually bland, which can be misleading. PubMed

12. Back/flank discomfort — occasionally with gout flares or late CKD. (Non-specific.) PubMed

13. Kidney failure symptoms — swelling, breathlessness, severe fatigue when CKD is advanced. MedlinePlus

14. Childhood anemia (ADTKD-REN) — low hemoglobin early in life is a tip-off for renin gene disease. PubMed

15. Family history — multiple relatives with gout/CKD across generations is a strong clinical clue. NCBI

---

Diagnostic tests

A) Physical exam / bedside assessment

1. Blood pressure measurement — often normal early; tends to rise as CKD advances; guides kidney-protective care. PubMed

2. Joint exam for gout — tender, red, swollen joints suggest urate crystal arthritis; tophi on ears/elbows help clinch the pattern. NCBI

3. Volume status check — signs of mild salt depletion (orthostatic dizziness) or, later, fluid overload; helps tailor salt and fluid advice. PubMed

4. Skin exam — tophi, scratch marks from itch in late CKD; supports the story. NCBI+1

5. Family pedigree mapping — charting affected relatives across generations strongly suggests autosomal-dominant inheritance and focuses genetic testing. NCBI

B) “Manual” or simple clinic tests/procedures

6. Urinalysis (dipstick & microscopy) — typically “bland” (trace or no protein, few cells), which separates ADTKD from many glomerular diseases. PubMed

7. Urine specific gravity or osmolality — shows reduced concentrating ability even before big drops in GFR. PubMed

8. 24-hour urine (optional) — can quantify urine volume and urate output; helpful when planning gout therapy. NCBI

9. Joint aspiration (arthrocentesis) when safe — identifies needle-shaped urate crystals under polarized light during a flare; confirms gout. NCBI

10. Ambulatory/home BP monitoring — better detects rising blood pressure as CKD advances. (General CKD practice applied to ADTKD.) PubMed

C) Laboratory and pathological tests

11. Serum uric acid — usually high from an early age; a key early clue. NCBI

12. Fractional excretion of urate (FEUA) — often inappropriately low; helps distinguish ADTKD-UMOD from other hyperuricemic states. NCBI

13. Serum creatinine & eGFR — track kidney function over time; decline is typically slow but steady. PubMed

14. Electrolytes & acid–base panel — ADTKD-REN can show hyperkalemia and metabolic acidosis in childhood; others are usually normal until late CKD. PubMed

15. Urinary uromodulin (ELISA, research/limited clinical labs) — frequently low in UMOD disease; supportive, not diagnostic on its own. Annual Reviews

16. Genetic testing (preferred diagnostic test) — targeted UMOD sequencing or a multi-gene ADTKD panel (UMOD, REN, MUC1, HNF1B, SEC61A1). MUC1 testing may require special assays. A positive result confirms the subtype, guides family testing and counseling. PubMed+1

17. Kidney biopsy (only if genetics are inconclusive) — shows interstitial fibrosis and tubular atrophy with relatively normal glomeruli; UMOD may accumulate in the ER of thick ascending limb cells. Genetics has largely replaced biopsy for diagnosis. PubMed

D) Electrodiagnostic tests (note)

1. There are no disease-specific electrodiagnostic tests for FJHN/ADTKD. Clinicians may order tests like an ECG (for general CKD or medication safety) or 24-hour BP monitoring to assess complications, but these do not diagnose the condition itself. This category is included here for completeness given your requested format. MedlinePlus+1

E) Imaging tests

1. Renal ultrasound — often normal early; later can show small, echogenic kidneys. Medullary cysts may occur in some allelic conditions historically labeled MCKD. PubMed

2. MRI or CT of kidneys (selected cases) — used when cysts or structural anomalies are suspected (e.g., with HNF1B). Imaging supports but does not define the diagnosis. PubMed

3. Musculoskeletal ultrasound or dual-energy CT of joints — detects tophi/urate deposition to support the gout component. NCBI

Non-pharmacological treatments (therapies and others)

1. Regular hydration
   Drinking enough water spreads uric acid out and helps the kidneys pass it into urine, which may lower flares of gout and kidney stones. For people with CKD, the “right” amount depends on stage, heart health, and sodium intake—so your clinician should personalize it. Hydration also supports blood pressure control by reducing the drive to retain salt. Over-hydration can be harmful in advanced CKD or heart failure, so targets should follow clinical advice. PubMed+1

2. Salt (sodium) restriction
   Keeping sodium under ~2,300 mg/day helps control blood pressure, a key factor that slows CKD progression. Less sodium also reduces fluid overload and may cut protein leak in urine for some CKD patients. Choose fresh foods, cook at home, and limit packaged or restaurant meals that hide salt. A renal dietitian can tailor sodium limits by CKD stage and labs. KDIGO+1

3. Blood pressure targets and home monitoring
   High blood pressure speeds up scarring in the kidney’s tubules and filters. Using a home cuff, logging readings, reducing salt, staying active, and taking prescribed BP medicines can slow kidney decline. Your team will set a target (often <130/80 mmHg) based on overall risk and CKD stage. KDIGO

4. Healthy body weight
   Gentle, steady weight loss (when appropriate) improves blood pressure, insulin resistance, and uric acid handling. A plant-forward pattern (vegetables, fruits in CKD-appropriate portions, whole grains as allowed, legumes, nuts in safe potassium amounts) supports a better acid-base balance and less kidney workload than a heavily processed diet. A renal dietitian can balance protein, potassium, phosphorus, and calories for your stage. AJKD+1

5. Renal dietitian–guided protein management
   In earlier CKD stages (not on dialysis), moderate protein intake can reduce uremic toxin load; in later stages or on dialysis, protein needs may rise. The kind of protein matters too: more plant protein may help acid load and gut microbiome. Work with a dietitian to avoid malnutrition while protecting kidneys. AJKD+1

6. Low-purine eating for gout control (within CKD limits)
   Gout risk rises when uric acid is high. Lower-purine choices (fewer organ meats and certain seafoods), limiting alcohol (especially beer), avoiding sugar-sweetened beverages (fructose), and focusing on low-fat dairy can help. These steps complement medicines if used. In CKD, portions must also respect potassium and phosphorus limits. Acr Journals

7. Avoidance of nephrotoxins (kidney-harming exposures)
   Non-steroidal anti-inflammatory drugs (many OTC painkillers), certain contrast dyes, and some herbal supplements can harm kidneys. When pain relief is needed, ask about safer options for CKD and gout flares. Always tell clinicians and pharmacists you have CKD so they can adjust or avoid risky drugs. KDIGO

8. Vaccinations and infection prevention
   People with CKD have higher infection risk and worse outcomes. Staying current on vaccines (e.g., influenza, pneumococcal, COVID-19 per local guidance) and prompt treatment of infections help protect remaining kidney function and overall health. KDIGO

9. Exercise most days
   Regular, moderate activity helps blood pressure, insulin sensitivity, weight, energy, and mood. Even walking 20–30 minutes on most days is helpful. Exercise plans should match CKD stage and your fitness level. KDIGO

10. Family genetic counseling and testing
    Because FJHN/ADTKD is often autosomal dominant, a parent with the variant has a 50% chance of passing it to each child. Genetic counseling helps families understand testing, timing, pregnancy planning, and living donor transplant screening in the future. NCBI

11. Stone prevention habits
    Hydration, balanced diet, and limiting fructose-sweetened beverages can reduce uric acid stone risk in susceptible people. Your team may check urine chemistry to personalize goals for citrate, pH, and volume. PubMed

12. Early planning for kidney replacement (if needed)
    If kidney function declines, learning about dialysis options and kidney transplant early reduces stress and improves outcomes. Transplant usually corrects the kidney failure; the genetic condition does not recur in the transplanted kidney. Living donor options in families require careful genetic and medical screening. KDIGO

---

Drug treatments

A. Uric-lowering and gout-flare medicines

1. Allopurinol (oral xanthine oxidase inhibitor)
   Class/Purpose. Allopurinol lowers uric acid to prevent gout flares and tophi. Dose/Timing. Start low and titrate; labels emphasize lower initial doses in CKD with gradual 50-mg/day steps to goal (per clinician). Mechanism. Inhibits xanthine oxidase, reducing uric acid production. Safety. Serious hypersensitivity (including SJS/TEN) can occur; dosing should reflect kidney function, and drug interactions are important. Note. For tumor lysis prevention there’s an IV form (allopurinol for injection), but that’s a different setting. FDA Access Data+1

2. Febuxostat (ULORIC; oral xanthine oxidase inhibitor)
   Class/Purpose. Lowers uric acid for gout prevention when allopurinol is not tolerated or inadequate. Dose/Timing. Label provides starting and maintenance doses; prophylaxis against flares is recommended when starting therapy. Mechanism. Selective xanthine oxidase inhibition. Safety. The FDA added a boxed warning for higher cardiovascular and all-cause mortality vs allopurinol in a safety trial; use is generally reserved for those who cannot use allopurinol. Contraindicated with azathioprine or mercaptopurine. FDA Access Data+2U.S. Food and Drug Administration+2

3. Probenecid (uricosuric)
   Class/Purpose. Increases uric acid excretion; used for chronic gout in selected patients with adequate kidney function. Dose/Timing. Label outlines titration schedules. Mechanism. Blocks tubular reabsorption of uric acid. Safety. Not effective in significant renal impairment and not for acute gout; risk of kidney stones—hydration and urine alkalinization may be advised. Numerous drug interactions (e.g., affects penicillin levels). FDA Access Data+1

4. Colchicine (for gout flares and prophylaxis)
   Class/Purpose. Antiinflammatory for acute gout flares and flare prophylaxis during initiation of urate-lowering therapy. Dose/Timing. Label provides low-dose acute regimen and prophylaxis dosing; adjust in CKD and with interacting drugs. Mechanism. Disrupts microtubules and inflammasome activation in neutrophils. Safety. GI upset, myopathy (especially with statins or CYP3A4/P-gp inhibitors), and toxicity if overdosed or with renal impairment—follow label. FDA Access Data+1

5. Pegloticase (KRYSTEXXA; IV uricase for refractory gout)
   Class/Purpose. Enzyme that converts uric acid to allantoin for severe, refractory gout when standard drugs fail. Dose/Timing. Given IV at set intervals; labels instruct to monitor serum uric acid and stop if it rises (loss of response means antibody formation). Mechanism. Pegylated uricase degrades uric acid directly. Safety. Infusion reactions and anaphylaxis; G6PD deficiency is a contraindication. Premedication and careful monitoring are required. FDA Access Data+1

6. NSAIDs (class: e.g., naproxen) for flares—use caution in CKD
   Purpose. Reduce pain/inflammation during acute gout, often short-course. Mechanism. COX inhibition. Safety. Many NSAID labels warn of kidney injury, GI bleeding, and cardiovascular risks; in CKD, NSAIDs are often avoided or used only if benefits clearly outweigh risks and after clinician approval. Consider alternatives (colchicine, steroids). (Representative FDA labels contain these warnings; choice must be individualized.) KDIGO

7. Oral glucocorticoids (e.g., prednisone) for flares—short courses
   Purpose. Anti-inflammatory for gout flares when NSAIDs/colchicine are unsuitable. Mechanism. Broad cytokine suppression. Safety. Short courses can raise glucose and blood pressure; longer or frequent courses have more risks. Use the lowest effective dose and shortest duration under medical supervision. (General CKD guideline context about minimizing nephrotoxin exposure and careful medication use.) KDIGO

B. CKD kidney-protection backbone (because gout control alone doesn’t halt ADTKD scar-ring)

8. ACE inhibitors (e.g., lisinopril) for blood pressure/proteinuria
   Class/Purpose. RAAS blockade improves BP control and may reduce albuminuria, slowing CKD progression in many causes of CKD. Dose/Timing. Titrate to BP/renal goals with monitoring. Mechanism. Blocks conversion of angiotensin I→II, lowering vasoconstriction and aldosterone. Safety. Watch for hyperkalemia, rising creatinine after start, and cough/angioedema. FDA Access Data+1

9. ARBs (e.g., losartan) for blood pressure/proteinuria; small urate benefit
   Class/Purpose. Alternative RAAS blockade when ACEIs aren’t tolerated. Mechanism. Blocks angiotensin II receptor. Urate note. Losartan has a mild uricosuric effect and can blunt thiazide-induced hyperuricemia, but the average urate drop is small (<0.4 mg/dL on chronic therapy in labeling). Safety. Monitor potassium and kidney function. FDA Access Data+2FDA Access Data+2

10. SGLT2 inhibitors (dapagliflozin, empagliflozin) in CKD
    Class/Purpose. For adults with CKD at risk of progression, FDA-approved to reduce sustained eGFR decline, ESKD, CV death, and HF hospitalization—regardless of diabetes status (see label indications). Dose/Timing. Once daily; label gives eGFR thresholds and precautions. Mechanism. Lowers proximal tubular sodium-glucose reabsorption, improving tubuloglomerular feedback and kidney hemodynamics. Safety. Volume depletion, mycotic infections; AKI risk warnings/monitoring in labels; follow eGFR-based use limits. (Note: Benefits apply to CKD broadly; specific trials in ADTKD are limited, so this is general CKD care.) FDA Access Data+3FDA Access Data+3FDA Access Data+3

---

Dietary molecular supplements

(These are adjuncts only—not substitutes for medical therapy. Always clear supplements with your clinician/dietitian in CKD.)

1. Vitamin C (low-to-moderate doses)
   Some studies show small uric-acid reductions with vitamin C; however, benefit is modest and high doses can increase oxalate—an issue for kidneys. In CKD, any supplement should be personalized and monitored. NIDDK

2. Omega-3 fatty acids (fish oil or algae-based)
   May help systemic inflammation, joint symptoms, and cardiometabolic risk—important in CKD. Dose and purity should be guided to avoid excess vitamin A/D or contaminants. AJKD

3. Vitamin D (if deficient, per labs)
   Correcting deficiency helps bone-mineral balance and parathyroid levels in CKD; dosing depends on labs and stage. Avoid excess without monitoring. AJKD

4. B-complex (especially folate/B12) when indicated
   B vitamins help correct certain deficiencies common in CKD and support anemia care when diet is limited; dosing is individualized. AJKD

5. Citrate sources (dietary/medical under supervision)
   Raising urinary citrate (and avoiding very acidic urine) can help prevent uric acid stones; specific regimens should be clinician-directed in CKD. PubMed

---

Drugs for immunity booster / regenerative / stem-cell

(Important safety note: there are no FDA-approved “stem-cell drugs” to regenerate kidneys in ADTKD/FJHN. Below are FDA-approved drugs relevant to complications—using labels as requested.)

1. Erythropoiesis-stimulating agents (ESAs; e.g., epoetin alfa, darbepoetin alfa)
   Used for CKD anemia to reduce transfusions; dosing is individualized to target hemoglobin ranges. These are not kidney-regenerative, but they treat a common CKD complication. (Use follows CKD anemia guidance; dosing/safety come from individual FDA labels.) KDIGO

2. Active vitamin D analogs (e.g., calcitriol) for CKD-MBD
   Used to manage secondary hyperparathyroidism in CKD, supporting bone/mineral balance. Again, not “regenerative,” but addresses a CKD-related endocrine issue. (Label-based use and risks like hypercalcemia apply.) KDIGO

3. SGLT2 inhibitors (dapagliflozin/empagliflozin)
   Discussed above: kidney-protective in CKD at risk of progression (not regenerative). FDA Access Data+1

4. RAAS blockers (ACEI/ARB)
   Cornerstones of CKD care for BP and albuminuria control; not “boosters,” but disease-modifying in many CKD settings. FDA Access Data+1

5. Sodium bicarbonate (medical therapy) for metabolic acidosis
   When indicated by labs, correcting acidosis may slow CKD decline in some patients; dosing must be individualized to avoid volume load and sodium issues. (Practice-guideline context.) KDIGO

6. Pegloticase (biologic enzyme)
   While not regenerative, it is a biologic that powerfully lowers uric acid in refractory gout, improving tophi and function when standard therapy fails—used in selected patients. FDA Access Data

---

Surgeries and procedures

1. Arteriovenous (AV) fistula creation
   If kidney failure develops and hemodialysis is chosen, a surgeon connects an artery to a vein (fistula) so it can handle dialysis flow. Fistulas last longer and have fewer infections than catheters. Planning early improves success. KDIGO

2. Peritoneal dialysis catheter placement
   For those choosing peritoneal dialysis, a soft tube is placed into the abdomen to exchange fluid that removes toxins and extra water. Many people value the home-based flexibility. KDIGO

3. Kidney transplant
   Transplant places a healthy donor kidney into the body to replace kidney function. ADTKD/FJHN does not recur in the transplanted kidney, so outcomes are based on usual transplant factors. Donors within the family should have genetic evaluation. KDIGO

4. Tophus debulking (select cases)
   In severe, deforming gout with large tophi that limit function or ulcerate, surgical removal may be considered after medical therapy optimizes urate. This is uncommon but can restore motion and reduce pain. Acr Journals

5. Parathyroid surgery (refractory secondary hyperparathyroidism)
   Rarely, in advanced CKD with uncontrolled parathyroid hormone despite medical therapy, surgery can protect bones and soft tissues from high-PTH damage. KDIGO

---

Preventions

1. Know your family history and consider genetic counseling/testing in at-risk relatives. NCBI

2. Keep blood pressure at target with lifestyle and medicines. KDIGO

3. Follow a sodium-smart eating pattern (<2,300 mg/day unless told otherwise). NIDDK

4. Stay well-hydrated (clinician-guided in CKD). KDIGO

5. Use low-purine, gout-friendly choices; limit alcohol and fructose-sweetened drinks. Acr Journals

6. Avoid NSAIDs and other nephrotoxins unless your clinician approves. KDIGO

7. Treat flares early with label-guided medicines to reduce pain and joint damage. FDA Access Data

8. Vaccinate and seek prompt care for infections. KDIGO

9. Plan ahead for dialysis or transplant if kidney function declines. KDIGO

10. Keep regular labs (eGFR, uric acid, potassium, bicarbonate, albuminuria) to adjust treatment in time. KDIGO

---

When to see a doctor (red flags)

See your clinician now for: a first gout flare; repeated or severe flares; sudden swelling, redness, or warmth in a joint; new flank pain or blood in urine (possible stones); rising blood pressure; leg swelling; shortness of breath; rapid changes in creatinine/eGFR; or symptoms of medication side effects (rash on allopurinol, chest pain on febuxostat, severe weakness or dark urine on colchicine). Regular visits every 3–12 months (timing by CKD stage) help catch problems early. KDIGO+3FDA Access Data+3FDA Access Data+3

---

What to eat & what to avoid (10 quick, kidney- and gout-smart tips)

Eat more (as labs allow):

1. Low-fat dairy, eggs, suitable plant proteins (portion-controlled)—they’re protein sources that can fit gout-friendly patterns. Acr Journals
2. Renal-dietitian–approved fruits/veg in amounts that respect potassium/phosphorus targets by CKD stage. National Kidney Foundation
3. Whole foods with less sodium; cook at home; use herbs/acid (lemon, vinegar) for flavor. NIDDK

Limit/Avoid:

1. High-purine meats (organ meats; some seafoods), beer/spirits, and fructose-sweetened beverages (drive uric acid up). Acr Journals
2. High-sodium packaged foods (canned soups, processed meats, instant noodles) that raise BP and fluid load. NIDDK
3. Very high-potassium or high-phosphorus foods beyond your lab-guided limits (certain dairy, nuts, colas, bran, some fruits/veg)—ask your dietitian for swaps. National Kidney Foundation+1

---

Frequently asked questions

1. Is FJHN the same as ADTKD?
   FJHN is now grouped within ADTKD, especially ADTKD-UMOD, because the disease pattern and gene causes overlap. NCBI

2. Will lowering uric acid stop my kidney disease?
   Lowering uric acid treats gout but has not been proven to halt the CKD scarring in ADTKD; you still need full CKD care. KDIGO

3. What uric-acid level should I aim for?
   Gout guidelines commonly target <6 mg/dL (lower in tophaceous gout), individualized to you. Acr Journals

4. Which is safer: allopurinol or febuxostat?
   Allopurinol is first-line for most; febuxostat carries an FDA boxed warning for higher CV death risk vs allopurinol and is often reserved for intolerance or contraindication to allopurinol. U.S. Food and Drug Administration

5. Can losartan lower uric acid?
   Yes, a little—labels describe a small uricosuric effect (average <0.4 mg/dL drop). It’s chosen mainly for BP/renal reasons. FDA Access Data

6. Are NSAIDs OK for gout if I have CKD?
   Often not preferred; many CKD patients avoid NSAIDs due to kidney risk. Ask about colchicine or short steroids instead. KDIGO

7. Do SGLT2 inhibitors help in ADTKD?
   They’re approved to protect kidneys in adults with CKD at risk of progression (class benefit), but ADTKD-specific trials are limited—discuss with your nephrologist. FDA Access Data

8. Will I need a transplant?
   Some people do over decades. Transplant outcomes are good, and ADTKD does not recur in the new kidney. KDIGO

9. What about genetic testing?
   It can confirm the diagnosis, guide family planning, and inform living-donor decisions. NCBI

10. Do I need to avoid all high-potassium foods?
    Only if your labs and stage say so; many patients can include some potassium with a dietitian’s help. National Kidney Foundation

11. Can cherries or vitamin C cure gout?
    They may help a little, but they don’t replace prescription urate-lowering therapy when indicated. Acr Journals

12. Is pegloticase a cure?
    It’s for refractory gout, not a cure for ADTKD. It powerfully lowers uric acid but requires IV infusions and careful monitoring. FDA Access Data

13. Are there stem-cell drugs to fix my kidneys?
    No FDA-approved stem-cell therapies regenerate kidneys in ADTKD/FJHN at this time. Care focuses on CKD protection and gout control. KDIGO

14. How often should I check labs?
    Your clinician will set intervals by CKD stage—commonly every 3–12 months for eGFR/albuminuria and more often when adjusting therapy. KDIGO

15. Can kids be affected?
    Yes; it’s autosomal dominant. Some genes (e.g., REN) show features in childhood. Genetic counseling helps families plan testing. Genetic & Rare Diseases Info Center

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 03, 2025.